Drug Profile
Flubrobenguane (18F) - Lantheus Medical Imaging
Alternative Names: 18F LMI 1195; LMI 1195-101; LMI-1195Latest Information Update: 06 Jul 2021
Price :
$50
*
At a glance
- Originator Lantheus Medical Imaging
- Class Fluorinated hydrocarbons; Fluorobenzenes; Guanidines; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Neuroendocrine tumours
- Discontinued Heart failure
Most Recent Events
- 06 Jul 2021 Discontinued - Phase-II for Heart failure (Diagnosis) (IV) (Lantheus Medical Imaging pipeline, July 2021)
- 06 Jul 2021 Phase-I clinical trials in Neuroendocrine tumours (Diagnosis, In adults) in USA (Parenteral) (Lantheus Medical Imaging pipeline, July 2021)
- 06 Jul 2021 Phase-I clinical trials in Neuroendocrine tumours (Diagnosis, In neonates, In infants, In children, In adolescents) in USA (Parenteral) (Lantheus Medical Imaging pipeline, July 2021)